产品
编 号：F352975
分子式：C26H29N5O3S
分子量：491.61
分子式：C26H29N5O3S
分子量：491.61
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 415903-37-6
产品详情
生物活性：
Grapiprant (CJ-023423) is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2). Grapiprant displaces [3H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor with IC50 value of 35 nM and Ki value of 24 nM. Grapiprant has the potential for osteoarthritic pain and inflammation treatment .
体内研究：
Grapiprant (0-50 mg/kg; oral administration; every 24 hours; for 9 months; beagles) is safe for dogs by long-term oral administration. Efficacy of Grapiprant in the treatment of dogs with osteoarthritis needs to be evaluated in other studies .Animal Model:36 beagles of both sexes (9-month-old)
Dosage:0 mg/kg, 1 mg/kg, 6 mg/kg, or 50 mg/kg
Administration:Oral administration; every 24 hours; for 9 months
Result:Long-term oral administration was safe for dogs.
Grapiprant (CJ-023423) is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2). Grapiprant displaces [3H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor with IC50 value of 35 nM and Ki value of 24 nM. Grapiprant has the potential for osteoarthritic pain and inflammation treatment .
体内研究：
Grapiprant (0-50 mg/kg; oral administration; every 24 hours; for 9 months; beagles) is safe for dogs by long-term oral administration. Efficacy of Grapiprant in the treatment of dogs with osteoarthritis needs to be evaluated in other studies .Animal Model:36 beagles of both sexes (9-month-old)
Dosage:0 mg/kg, 1 mg/kg, 6 mg/kg, or 50 mg/kg
Administration:Oral administration; every 24 hours; for 9 months
Result:Long-term oral administration was safe for dogs.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备